Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years

Thalange, Nandu; BEREKET, ABDULLAH; Jensen, Lisbeth; Hiort, Line; Peterkova, Valentina

doi:10.1007/s13300-016-0196-5

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years

Atıf İçin Kopyala

Thalange N., BEREKET A., Jensen L. B., Hiort L. C., Peterkova V.

DIABETES THERAPY, cilt.7, sa.4, ss.713-724, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 7 Sayı: 4
Basım Tarihi: 2016
Doi Numarası: 10.1007/s13300-016-0196-5
Dergi Adı: DIABETES THERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.713-724
Marmara Üniversitesi Adresli: Evet

Özet

To study the long-term development (104 weeks) of insulin antibodies during treatment with insulin detemir (IDet) and insulin aspart (IAsp) in children with type 1 diabetes aged 2-16 years.